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Background: YKL-40 is a secreted inflammatory protein that its overexpression has been reported to correlate with
poor outcome of various malignant diseases, especially in cancer. However, the function of this protein is still unclear.
Methods: The clinical prognosis of non-small cell lung cancers (NSCLC) patients and their clinical YKL-40 expressions
were obtained from the Prognoscan database. The expressions of YKL-40 in patient samples were determined by
Western Blotting assay. YKL-40 gene knockdown and overexpression were performed on NSCLC cancer cells (CL1-1
and CL1-5). The cells were investigated for their epithelial–mesenchymal transition (EMT) markers gene modulation
through Western Blotting and RT-PCR. Further cell metastatic abilities were assessed by transwell migration and
invasion assay.
Result: In this study, YKL-40 was observed to be highly expressed in NSCLC specimens. Furthermore, determined by
the PrognoScan database analysis, patients with high expression levels of YKL-40 were found with poor prognosis. In
the in vitro study, different characteristics of NSCLC cell lines (CL1-1, H23, H838, CL1-5, and H2009) were used as study
models, where YKL-40 expression levels were determined to correlate with the phenotypic characteristics of cancer
metastasis. In this study,YKL-40 was demonstrated to regulate EMT marker expressions such as Twist, Snail, Slug,
N-cadherin, Vimentin, and E-cadherin. The protein’s affects in cancer cell migration and invasion were also observed in
YKL-40 overexpression or knock down NSCLC cell lines.
Conclusion: All of results from this study suggest that YKL-40 is a major factor in NSCLC metastasis. Thus, YKL-40 may
serve as therapeutic target for NSCLC patients in the future.Background
Lung cancer is the leading cause of cancer death and its
prevention is a major worldwide challenge. Non-small
cell lung cancer (NSCLC) accounts for more than 80 %
of lung cancers [1, 2]. The classifications of NSCLC
include large cell carcinoma, adenocarcinoma, and squa-
mous cell carcinoma. Approximately one-half of lung
cancers become metastatic, and the most common sites
of metastasis are found in the lymph nodes, liver, adrenal
glands, bone, and brain. The most frequently reported
lung carcinoma subtype is lung adenocarcinoma. In
the past decades, many genes have been found to be* Correspondence: wenurea@yahoo.com.tw
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from these modulated genes, such as Wnt5A, KFL6,
cyclin D1, ER-α, UPA, PAI-1, HER2, and c-myc, were
determined with essential roles in cancer initiation and
progression [3–5]. Among the upregulated proteins,
YKL-40 was frequently proposed for its role in cancer
metastasis [6–8].
YKL-40, a member of mammalian chitinase-like pro-
teins, is overexpressed in many pathological conditions
that includes fibroblastic change in liver cirrhosis,
increased deposition of connective tissue components
and hyperplastic synovium in rheumatoid arthritis, and
increased cellular infiltration as well as epithelial prolif-
eration in chronic colitis [4]. YKL-40 is also up-
regulated in many chronic inflammatory conditions such
as inflamed tissues in ulcerative colitis, Crohn’s disease,
rheumatoid arthritis, osteoarthritis, asthma, chronicis distributed under the terms of the Creative Commons Attribution 4.0
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The levels of YKL-40 were determined to be upregulated
in in solid cancers arising from bone, brain, breast, cartil-
age, cervix, colon, germ cell, head and neck, kidney, liver,
lung, lymph node, ovary, pancreas, prostate, skin, and thy-
roid, when compared with their respective normal tissues
or cells [5–7]. Aside from its association with inflamed tis-
sues, YKL-40 expression is also regulated by many inflam-
matory cytokines. It is believed that inflammatory
mediators such as pro-inflammatory cytokines of IL-1,
TNF-α, IL-6, and IL-13, regulate YKL-40 expression in
inflammatory conditions [8]. Furthermore, YKL-40 expres-
sion is also controlled by hormones such as vasopressin,
and parathyroid hormone-related protein in both macro-
phages and epithelial cells [9, 10]. Despite the association
of increased expression of YKL-40 with many diseases, its
biological function is still largely unknown. Further studies
have determined that YKL-40 interacts with many compo-
nents of the extracellular matrix (ECM), including hyalur-
onic acid, fibronectin, and collagen I, II, III and IV [11].
The ability to adhere to extracellular matrix is especially
important for cancer cell migration and invasion [4, 12].
YKL-40 protein is involved in proliferation of fibroblasts
and modulation of collagen formation, facilitating tumor
invasion, and metastasis [13]. These mesenchymal func-
tions have been verified in a microarray analysis with high-
grade gliomas. The analyses determined that YKL-40 is
upregulated, together with other genes, in mesenchymal
tissues and are associated with poor prognosis (adult
malignant gliomas) [14, 15]. However, the function of
YKL-40 in cancer metastasis is still unclear.
Therefore, this study, was aimed to investigate the
relationship between YKL-40 and tumor migration and
invasion in NCLC. The phenotypic characteristics of
YKL-40 NSCLC cell lines were determined and com-
pared. Further analysis was performed to determine the
influence of YKL-40 in regulating EMT through the
AKT signaling pathways for enhanced cancer migration
and invasion. We believe that YKL-40 may serve as
therapeutic targets for NSCLC patients in the future.
Materials and methods
Patients and tissue samples
Ten de-identified tumor samples (each includes NSCLC
and normal control patients) were obtained from the
Shuang Ho Hospital Resource Center (New Taipei city,
Taiwan). The patients in this study were free from any
inflammatory conditions. Written informed consents
were obtained from the patients and this study was ap-
proved by the ethics committee of Shuang Ho Hospital.
NSCLC cell lines and cell culture
Human adenocarcinoma cell lines H838, H23, and
H2009 were purchased from American Type CultureCollection (Manassas, VA), while CL1-1 and CL 1–5 were
kind gifts from Dr. Pan-Chyr Yang of National Taiwan
University. Cells were cultured in RPMI 1640 medium
(GIBCO, Gaithersburg, MD) containing 10 % fetal bovine
serum (FBS) (Jacques Boy, Reims, France), 100 U/mL of
penicillin (GIBCO) and 100 U/mL of streptomycin
(GIBCO) at 37 °C in a 5 % CO2 atmosphere at 99 %
humidity.
Generation of YKL-40 stable expression CL1-1 cell lines
The full length of YKL-40 cDNA was isolated directly
from a NSCLC CL1-5 cDNA library using the polymer-
ase chain reaction (PCR) and introduced restriction sites
for BamHI and HindIII. After sequence confirmation,
the full-length YKL-40 was cloned into the reporter vec-
tor pEGFP-C1 to yield the reporter plasmid. The NSCLC
CL1-1 cells were transfected with 2 μg of YKL-40 or
vector control DNA using TurboFect™ reagent (Fermentas,
Glen Burnie, MD) as the delivery vehicle. Selection with
800 μg/ml of G418 was performed at 24 h after transfec-
tion, and the drug-resistant cell populations were used for
subsequent studies.
Generation of YKL-40 stable knockdown CL1-5 cell lines
TurboFect™ (Fermentas, Glen Burnie, MD) was used to
deliver plasmid DNA containing small hairpin RNA
(shRNA) against human YKL-40(OriGene, Rockville,
MD) into NSCLC CL1-5 cells in a 24-well culture plate.
Selection with puromycin was performed at 24 h after
transfection, and the drug-resistant cell populations were
used for subsequent studies.
Generation of YKL-40 stable knockdown and
re-overexpression CL1-5 cell lines
After the stable culture YKL-40 knockdown CL1-5 cells,
the cells were transfected with 2 μg reporter vector
(DsRed plasmid), which contained the full-length YKL-40
gene, using TurboFect™ reagent (Fermentas, Glen Burnie,
MD) as the delivery vehicle. Selection with 800 μg/ml of
G418 was performed at 24 h after transfection, and the
drug-resistant cell populations were used for subsequent
studies.
Migration assay
Cells were harvested and suspended in RPMI 1640
medium containing 10 % FBS at a concentration of 1 ×
106 cells/mL. A transwell apparatus with 8 μm pore size
membrane (Millipore, Billerica, MA) was used to analyze
the migration activity. In brief, suspension of cells in 100
μL of serum-free RPMI 1640 medium were seeded into
the upper chamber of the apparatus, 250 μL of RPMI
containing 10 % FBS were added to the insert well, and
the apparatus was incubated at 37 °C for 6 h. After incu-
bation, the inner wall of the chambers were wiped with
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the chambers were gently rinsed with PBS and stained
with Giemsa (Sigma-Aldrich, St. Louis, MO) for 10
mins. Finally, the membrane was rinsed and allowed to
air-dry. The membrane in triplicate was photographed
and the number of cells counted.
Invasion assay
Invasion assay was performed by a modification of the
method described previously. A 100 μL Matrigel (Becton
Dickinson, Franklin Lakes, NJ) was diluted to 1 mg/mL
in serum-free RPMI. This solution was added to each
upper chamber of the transwell with 8 μm pore size
membrane. After solidification of Matrigel at 37 °C,
approximately 1 × 105 cells in serum-free RPMI were
seeded onto the Matrigel over the upper chamber,
followed by the addition of 250 μL of RPMI containing
10 % FBS at the bottom insert-well. After incubation of
the cells at 37 °C for 18 h, the inner wall of the cham-
bers were wiped with wet swabs to remove the cells,
while the outer wall of the chambers were gently rinsed
with PBS and stained with the Giemsa stain solution for
10 mins. Finally, the membrane was rinsed and allowed
to air-dry. The membrane in triplicate was photographed
and the number of cells counted.
Western blot analysis
The electrophoretic experiments were performed by
SDS-PAGE (10 % polyacrylamide unless specified other-
wise) to analyze the YKL-40 and EMT related genes.
Electrophoresis was conducted by a vertical gel electro-
phoresis device that was powered by (Mini PIII, Bio-Rad,
Hercules, CA) a PAC 300 power supply (Bio-Rad). All
SDS-PAGE samples (20 μg) were equilibrated in 10 mM
Tris–HCl and 5 % SDS (pH 7.6) before loading.
Following complete separation, the gel was soaked
briefly in a transfer buffer, which contained 25 mM Tris,
192 mM glycine, 20 % methanol, and 0.0375 % SDS (pH
8.3), for 30 s. The gel was then immediately electrotrans-
fered to a nitrocellulose membrane (Hybond-ECL extra;
Amersham) at 90 mA for 60 mins in a semi-dry Trans-
fercell (Bio-Rad). The membrane was immersed in 2 %
skim milk for 1 h with gentle agitation. After three
washes with PBS for 5 mins each, the membrane was
subjected to react with monoclonal or polyclonal anti-
bodies and developed with chemiluminescence agents.
Reverse transcription polymerase chain reaction (RT-PCR)
The YKL-40 mRNA levels in the NSCLC cells was de-
termined by RT-PCR. Total RNA was extracted from
the cells using TRIzol (Invitrogen Corporation, San
Diego, CA). Following spectrometric determination of
RNA yield, cDNA was synthesized with oligo (dT) pri-
mer using Moloney Murine Leukemia Virus (MMLV)Reverse Transcriptase. An aliquot of cDNA was sub-
jected to 35 cycles of PCR using a standard procedure
of initiation at 65 °C for 5 mins, incubating at 37 °C for
2 mins, and inactivating at 70 °C for 15 mins. The amp-
lified products were resolved in a 1 % agarose gel and
visualized by Sybr safe staining.
Bioinformatics
The associations between gene expression levels and
NSCLC patients prognosis were obtained from the Prog-
noScan database [16]. PrognoScan is a large collection
of publicly available cancer microarray datasets with
clinical annotation and a tool for assessing the biological
relationship between gene expression and prognosis. In
the PrognoScan database, association of gene expression
with survival of patients was evaluated by the minimum
P value approach. Briefly, patients were first arranged by
expression levels of a given gene. They were then di-
vided into high- and low-expression groups at all pos-
sible cutoff points, and the risk differences between any
2 groups were estimated by the log-rank test. Finally, the
cutoff point that resulted the most pronounced P value
was selected.
Meanwhile, the mRNA expression of YKL-40 among
cancer patients and healthy population were mined from
The Cancer Genome Atlas (TCGA) database and ana-
lysed using BoxPlotR.
Statistical analysis
Data are presented as mean ± standard deviation (SD)
The difference between the groups were calculated by
Student t test (2 tailed). A p value of < 0.05 was taken as
the indication of statistical significance.
Results
YKL-40 was highly expressed in NSCLC patients and was
correlated with poor prognosis
Several NSCLC patients were investigated in this study,
where consistently higher expressions of YKL-40 were
observed in tumor than in non-tumor cells (Fig. 1a).
Similar result were found in our immunohistochemistry
staining analysis that compared the YKL-40 expression
of normal lung cells and lung tumor cells (Fig. 1b).
These results were further confirmed through TCGA
analysis, by comparing YKL-40 expression between nor-
mal and lung adenocarcinoma as well as lung squamous
carcinoma populations. The analysis determined that
YKL-40 expressions were highly upregulated among
lung carcinoma populations (Fig. 1c). Finally, we investi-
gated the correlation of YKL-40 expression and NSCLC
patient prognosis using the PrognoScan database
(http://www.prognoscan.org/). As shown in Fig. 1d,
high expression of YKL-40 was correlated with poor
NSCLC patient prognosis.
Fig. 1 a Western Blot analysis comparison of YKL-40 gene expressions in normal lung tissues and non-small cell lung cancer (NSCLC). b YKL-40
immunohistochemistry staining comparison between normal lung tissue and lung tumor tissue (200 x magnification). c YKL-40 expression
comparison analysis between normal lung cell and lung adenocarcinoma (Luad) & Lung squamous carcinoma (Lusc), *, P < 0.05, **, P < 0.005 (d)
The correlation between YKL40 expression and NSCLC patient prognosis. Comparison of YKL40 expression and patient prognosis was examined
using the Prognoscan database
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in NSCLC
To investigate the effect of YKL-40 expression level for
tumor migration and invasion in NSCLC, five NSCLC
cell lines (CL 1–1, CL 1–5, H23, H838, and H2009) were
used for the evaluation of their migration/invasion abil-
ities and YKL-40 expression levels. As shown in Fig. 2a,
cell lines that had high migration activities were corre-
lated, in general, with their high invasion. The cells were
divided into low (CL 1–1 and H23) and high (H838, CL
1–5 and H2009) migration/invasion groups. Figure 2b
shows that the cell lines with higher migration/invasion(H838, CL 1–5 and H2009) had greater YKL-40 mRNA
and protein expression levels (determined by RT-PCR and
Western blot), when compared with those that exhibited
lower migration/invasion abilities (CL 1–1 and H23).
Tumor invasion/migration effect of YKL-40 in NSCLC cell line
To investigate the effect of YKL-40 on cancer cell migration/
invasion, YKL-40 knockdown in CL1-5 cells and YKL-40
overexpression in CL1-1 cells were constructed. After estab-
lishing the stable knockdown and overexpression cell lines,
YKL-40 gene was transfected to re-overexpress in YKL-40
knockdown CL1-5 cells and re-knockdown of the CL1-1,
Fig. 2 The effect of YKL-40 expression level on the invasion and migration abilities of the NSCLC cell lines. a The five NSCLC cell lines were divided into
low metastasis (CL1-1, H23) and high metastasis (H838, CL1-5, H2009) groups by invasion and migration assay. b The YKL-40 expression level analysis
by reverse transcription polymerase chain reaction (RT-PCR) and Western blot: indicating that the low and high metastasis groups expressed reduced
and increased levels of YKL-40 mRNA and protein, respectively
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RT-PCR and Western blot in our cell lines are shown in
Fig. 4a and b. The YKL-40 mRNA expression was substan-
tially attenuated in YKL-40 knockdowned-cell and
overexpression-reknockdown cell, when compared with
cells without YKL-40 knockdown or the vector control.
The YKL-40 gene was down-regulate to 6.9 % in the
YKL-40 knockdowned CL 1–5 and had 35 %/22 % de-
crease in invasion/migration, when compared with the
controls (Fig. 3a, b). The YKL-40 gene was up-
regulated to 825 % in YKL-40 overexpression CL 1–1,which exhibited a 370 %/448 % increase of invasion/mi-
gration when compared with the controls (Fig. 3c, d). The
YKL-40 overexpression-reknockdown CL1-1 cell was
demonstrated to reverse its invasion/migration ability
(Fig. 3a and b). Similarly, the YKL-40 knockdowned CL1-
5 cell exhibited decreased ability of invasion/migration,
when compared with the CL1-5 wild type. The inva-
sion/migration ability of YKL-40 knockdowned CL1-5
cell was reversed when YKL-40 was re-overexpressed
(Fig. 3c and d). Furthermore, the metastatic abilities of
these cells were also confirmed in vivo. Four CL1-1 cell
(I) CL1-5.wt (III) CL1-5.KD (IV) CL1-5.KD.YKL-40(II) CL1-5.Vec




(I) CL1-1.wt (III) CL1-1.YKL-40
B. Migration assay
(IV) CL1-1.YKL-40.KD(II) CL1-1.Vec 
(I) CL1-1.wt (III) CL1-1.YKL-40(II) CL1-1.Vec (IV) CL1-1.YKL-40.KD
E. In vivo study
Fig. 3 (See legend on next page.)
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Fig. 3 a and b CL1-1 cells (I) were transfected with the green fluorescent protein (GFP) expression plasmid (pEGFP-C1) plasmid, encoding empty
vector (II) or full-length YKL-40 (III). After stable expression, cells were knockdowned via shRNA against human YKL-40 (IV). Four cells were sub-
jected to Matrigel invasion assay (a) and transwell migration assay (b). c and d CL1-5 cells (I) were transfected with shRNA vector control (II) or
shRNA against human YKL-40 (III). The cells were then co-transfected with the DsRed plasmid encoding YKL-40 (IV). The ability of these four cells
to invade through Matrigel (c) or to migrate (d) was assayed. Mean ± transwell assay was determined by three independent experiments; statis-
tical significance was measured using one way ANOVA, *, P < 0.05, **, P < 0.01, ***, P < 0.001. e in vivo study of each transfected cell lines’ migra-
tion ability. Each transfected cell lines were injected into nude mice for 6 weeks before lung harvest and lung nodules number determination.
This experiment was conducted in triplicates for each group
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YKL-40 knockdown-reoverexpression) were injected
into nude mice for 6 weeks and the number of meta-
static lung tumor nodules were determined. The num-
ber of tumor nodules of the YKL-40 overexpression cells
were significantly higher than those of the other groups
(Fig. 3e). Overall, the results showed that an increase of
YKL-40 expression can significantly enhance cancer mi-
gration/invasion and vice versa. This suggest that YKL-40
expression is associated with of NSCLC cells migration/
invasion.
YKL-40 promotes cell migration/invasion ability via
regulating EMT related genes in NSCLC cells
To investigate the correlation between YKL-40 and EMT
related-genes for promoting migration/invasion capability
of NSCLC, several EMT-associated genes such as adhe-
sion markers E-cadherin and N-cadherin; transcription
regulators Twist, Snail and Slug; and cytoskeleton
organization marker Vimentin in YKL-40 overexpressed-
CL 1–1 and YKL-40 knockdowned-CL 1–1 (Fig. 4) were
analyzed. The results suggested that mesenchymal
markers (N-cadherin and Vimentin) were up-regulated
and epithelial markers (E-cadherin) was down-regulated
in YKL-40 overexpressed CL1-1. Moreover, EMT activa-
tors (Twist, Snail and Slug) were also up-regulated after
YKL-40 overexpression in CL1-1. The results can also
be reversed after YKL-40 gene reknockdown of YKL-
40-overexpressed-CL1-1. Mesenchymal makers and regu-
lators, and epithelial markers were determined to be
decreased and increased, respectively, in YKL-40 over
expression-reknockdowned CL1-1, when compared to
YKL-40 overexpressing CL1-1 (Fig. 4a). Likewise, YKL-40
knockdown CL1-5 exhibited repressed mesenchymal
markers, and enhanced epithelial markers mRNA and pro-
tein level expression. However, the YKL-40 knockdown-
reoverexpression CL1-5 cells underwent complete EMT
markers expression reversion (Fig. 4b).
Discussion
In the past decades, numerous of studies have found genes
with modulated expressions in cancer cells. Most of these
modulated genes hold important roles that involved sus-
tained proliferative signaling, evading growth suppressors,activating invasion and metastasis, enabling replicative im-
mortality, inducing angiogenesis, and resisting cell death
[17]. Among all of these genes, multitude of clinical stud-
ies have determined that an abnormal up-regulation of
YKL-40 is associated with cancer metastasis and poor pa-
tient survival [6, 18, 19]. In our study, each highly migrat-
ing/invading NSCLC cell lines (CL1-5, H838, and H2009)
and surgical specimens from NSCLC patients exhibited
higher expression of YKL-40 when compared to the con-
trols (Figs. 1 and 2). Moreover, the expression of YKL-40
was determined to positively correlate with poor prognosis
in NSCLC patients using the PrognoScan database
(Fig. 2a). A number of studies have indicated that high
serum levels of YKL-40 are correlated with higher metas-
tasis and poor survival in a variety of human carcinomas
[5, 17, 20]. At the time of diagnosis, 39 % to 91 % of pa-
tients with metastatic disease had elevated serum levels of
YKL-40 [5]. However, the relationship between metastasis
and YKL-40 expression level in tissues is not clear. Many
studies have suggested that YKL-40 may have a role in
cancer cell proliferation, survival, and invasiveness dur-
ing the inflammatory process around the tumor, angio-
genesis, and remodeling of the extracellular matrix [15].
Thus, transwell migration/invasion assay was performed
to investigate the role of YKL-40 in cancer migration and
invasion. Our results indicated that after YKL-40 gene
overexpression, the migration and invasion ability of CL1-
1 NSCLC cell lines were increased significantly, and can
be reversed after further YKL-40 knockdown (Fig. 3a). On
the other hand, YKL-40 gene knockdowns exhibited atten-
uated migration and invasion ability in CL1-5 NSCLC cell
line, where the cells regains mobility after YKL-40 re-
overexpression (Fig. 3b). In the past few years, it has
been understood that cancer cells undergo EMT repro-
gramming to equip the cells with progression-
associated capabilities for migration/invasion [21].
Numerous observations supported the idea that EMT
is an important event in the progression, invasion, and
metastasis of carcinomas, which may be a permanent
feature in carcinomas that have a particularly dismal
prognosis [22–24]. In our study, we explored the role of
YKL-40 in EMT and determined that YKL-40 induces
EMT progression (Fig. 4). The results indicated that the
expression of E-cadherin, a marker of epithelial cells,
Fig. 4 The epithelial–mesenchymal transition (EMT) marker expression regulation in modulated YKL-40 gene expression NSCLC. a EMT markers
expression analysis of YKL-40 overexpressed CL1-1 cell (I) and YKL-40 reknockdown of YKL-40 overexpressed CL1-1 cell, as well as b EMT markers
expression analysis of YKL-40 knockdowned CL1-5 cell (I) and YKL-40 re-overexpression of YKL-40 knockdowned CL1-1 cell using RT-PCR and
Western Blot analysis. Mean ± transwell assay were determined by three independent experiments; statistical significance was measured using
one way ANOVA, *, P < 0.05, **, P < 0.01, ***, P < 0.001
Fig. 5 The schematic representation of EMT markers regulation by YKL-40, resulting in the induction of EMT
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Vimentin, markers of mesenchymal cells, was significantly
higher in YKL-40 overexpressed cell line, when compared
to the control group. Other EMT inducers (or regulators),
such as Snail, Slug, and Twist, have also been shown with
remarkably higher expressions. It was clearly demon-
strated in our findings that YKL-40 expression level corre-
sponds greatly with that of the EMT genes. This result
implies that YKL-40 promotes the migration and invasion
of cancer cell by regulating EMT genes. Previous studies
have also reported that YKL-40 may play a role in the
regulation of phosphatidylinositol 3 kinase (PI3K)/AKT/
mTOR pathway or Ras/Raf/MEK/ERK cascade, which is
one of the best-studied signal transduction pathways con-
nected with tumor survival, transformation, invasion, and
metastasis [25, 26]. In the meantime, the activation of
PI3K/AKT axis is emerging as a central feature of EMT,
which is a well-known cancer migration and invasion
enhancement pathway [21]. This study may bridge the
two previous findings, where YKL-40 was determined to
promote migration and invasion of cancer cells by regulat-
ing EMT essential genes via AKT signaling pathway. Our
results indicated that YKL-40 has the potential to be a
therapeutic target for cancer therapy. Furthermore, the
study on the therapeutic potential of YKL-40 has been
conducted by Faibish et al. by using YKL-40 targeting
monoclonal antibody, where tumor angiogenesis and
growth was effectively inhibited [27]. Thus, it can be con-
cluded that YKL-40 possess an important role in tumor
initiation and progression.Conclusions
In conclusion, our finding revealed the important role of
YKL-40 in promoting cancer metastasis. The expression
level of YKL-40 corresponds highly with the migration
and invasion ability of NSCLC. YKL-40 promotes cancer
metastasis by regulating EMT essential genes (Fig. 5).
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